Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders
Advanced Science · 2026-09 · 13 (50)
DOI: 10.1002/advs.77142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 11.08.2026. Verfasst von Kaige Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Protein Engineering, Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: METAVIVOR Foundation Early Career Research Grant Award to Q.H., American Cancer Society Research Scholar, NIBIB NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Targeted chimeras have reshaped therapeutic design by converting target recognition into active degradation. As one of the most clinically established therapeutic modalities, antibodies provide high affinity and specificity to the protein of interest. Antibody‐associated targeted chimeras (AbTACs) are emerging as an important class of biologic degraders for targeted protein elimination, particularly of extracellular and membrane‐associated proteins. AbTACs offer a strategy to extend its recognition capacity beyond target binding by coupling defined degradation pathway. In these systems, antibody‐derived binders serve as programmable recognition modules, while conjugated ligands, encoded domains, recruited receptors, or nanoparticle scaffolds determine the target's intracellular fate. This review discusses the conceptual evolution of AbTACs and classifies current platforms according to scaffold architecture and engineering strategies, which link target binding to intracellular routing and subsequent clearance. Furthermore, it highlights the design principles and translational barriers that will guide the development of next‐generation antibody‐associated degraders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Lachman Institute for Pharmaceutical Development, University of Wisconsin, Madison, Wisconsin, USA.
ORCID-Profile: Quanyin Hu
Förderung
- METAVIVOR Foundation Early Career Research Grant Award to Q.H., American Cancer Society Research Scholar
- NIBIB NIH HHS
- NCI NIH HHS
- start-up package from the University of Wisconsin-Madison
- Lachman Institute Research Funds, and Joseph R. and Bonna A. Robinson Chair fund
- University of Wisconsin Carbone Cancer Center Research Collaborative and the Pancreas Cancer Task Force
- National Institute of Biomedical Imaging and Bioengineering
- National Cancer Institute
Zitieren
APA
Chen, K., & Hu, Q. (2026). Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders. Advanced Science, 13(50). https://doi.org/10.1002/advs.77142
Vancouver
Chen K, Hu Q. Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders. Advanced Science. 2026;13(50). doi:10.1002/advs.77142
BibTeX
@article{Chen2026,
author = {Chen, Kaige and Hu, Quanyin},
title = {Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {50},
doi = {10.1002/advs.77142}
}
EUVIMED